4.5 Article

One size does not fit all: navigating the multi-dimensional space to optimize T-cell engaging protein therapeutics

Journal

MABS
Volume 13, Issue 1, Pages -

Publisher

TAYLOR & FRANCIS INC
DOI: 10.1080/19420862.2020.1871171

Keywords

Bispecific engineering; cd3; t-cell engager; therapeutic window

Ask authors/readers for more resources

The research compared a bispecific diabody-Fc with a bispecific IgG in terms of antigen epitope location and molecular formats, showing different effects on immunological synapse formation and cytotoxicity at different antigen epitope positions. Additionally, exploration of parameters including receptor density, antigen-binding affinity, and kinetics was conducted.
T-cell engaging biologics is a class of novel and promising immune-oncology compounds that leverage the immune system to eradicate cancer. Here, we compared and contrasted a bispecific diabody-Fc format, which displays a relatively short antigen-binding arm distance, with our bispecific IgG platform. By generating diverse panels of antigen-expressing cells where B cell maturation antigen is either tethered to the cell membrane or located to the juxtamembrane region and masked by elongated structural spacer units, we presented a systematic approach to investigate the role of antigen epitope location and molecular formats in immunological synapse formation and cytotoxicity. We demonstrated that diabody-Fc is more potent for antigen epitopes located in the membrane distal region, while bispecific IgG is more efficient for membrane-proximal epitopes. Additionally, we explored other parameters, including receptor density, antigen-binding affinity, and kinetics. Our results show that molecular format and antigen epitope location, which jointly determine the intermembrane distance between target cells and T cells, allow decoupling of cytotoxicity and cytokine release, while antigen-binding affinities appear to be positively correlated with both readouts. Our work offers new insight that could potentially lead to a wider therapeutic window for T-cell engaging biologics in general.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available